Our projects

Brilliant scientists, powerful collaborations. We find and fund projects that are ripe for impacting Duchenne now.

Access to best care and new treatments

We are proud to have invested in research and care improvement that is already making a difference to those living with Duchenne, and their families. Click below to learn more.

Duchenne Care UK: Best Care For All

Duchenne Care UK is a national initiative funded by Duchenne UK, Duchenne Research Fund and Joining Jack to make care better for everyone with Duchenne, across the UK, at all stages of life.

Duchenne Care UK Psychosocial

We are focused on improving provision and access to the best psychological and psychiatric support, as well as best practice in schools for neurodivergent children with Duchenne.

Vamorolone

We are proud to have been a Phase I funder of vamorolone, an alternative steroid treatment for Duchenne, which is now approved in the UK, US and EU. Following a NICE approval process, it is now available on the NHS.

Duchenne Care UK Psychosocial Working Group
Duchenne Care UK psychosocial working group
Sheli Rodney, Emily Reuben, Prof Katie Bushby, Prof Michela Guglieri, Alex Johnson, Eric Hoffman
Funders and clinicians involved in vamorolone success

Gene therapy progress

The underlying cause of Duchenne is the lack of dystrophin produced by the dystrophin gene. While there are some promising new treatments that help to slow progression or alleviate symptoms, most treatments do not tackle this underlying genetic mutation. We have funded a range of gene therapies which aim to correct the mutation in the dystrophin gene. There has been promising progress in this area and a number of gene therapies have reached the clinical trial stage. Read below to learn more about the research we have funded.

Gene therapy for Duchenne

Solid Biosciences’ ground-breaking gene therapy programme for Duchenne.

CRISPR for Duchenne muscular dystrophy

A novel gene editing approach to correct the mutated dystrophin gene.

Gene therapy for Becker

A microdystrophin gene therapy approach for Becker muscular dystrophy.

Grants and awards for clinicians and facilities

Melis Sevim

Neuromuscular and clincial research dietitian, Great Ormond Street Hospital

Luca Bello, University of Padua, Italy

World Muscle Society Congress prize

Cathy Turner

Duchenne Care UK Senior Project Manager, John Walton Muscular Dystrophy Research Centre

Adam Kerr

Duchenne Care UK Project Coordinator, John Walton Muscular Dystrophy Research Centre

Kathy Wang

HHMI Medical Research Fellowship

Nicola Burnett

Senior physiotherapist, Great Ormond Street Hospital

Dr Michela Guglieri

Newcastle Senior Clinical Lecturer and Neurologist

Manju Agarwal

Clinical trial co-ordinator at Great Ormond Street Hospital

Refurbishment and expansion of paediatric space

Clinical Research Facility at Newcastle Royal Infirmary

The DRF has invested in a diverse range of pre-clinical and clinical research programmes to tackle the complex nature of Duchenne muscular dystrophy: from anti-inflammatory treatments, to novel methods of delivering gene therapies into the body, to ways to adapt the immune system to better receive treatments, as well as novel biomarkers – ways to measure which treatments are working and how quickly. Click below to learn more about what we have funded.

Activity monitoring biomarker

KINEDMD: Wearable sensor technology to monitor Duchenne patients’ activity.

Combating immunity to AAV

Ensuring as many patients as possible can benefit from gene therapy.

Blood-based biomarker

Measuring disease progression and response to new treatments.

Non-viral delivery

A next-generation gene therapy delivery approach.

Non-invasive imaging biomarker

Reducing biopsies and improving dystrophin analysis in Duchenne boys.

SMT C1100

Increasing utrophin to compensate for dystrophin.

Ringo

Dystrophic dogs provide insights into Duchenne research.

Neurobehavioural issues in Duchenne

Tackling learning, behaviour, depression and anxiety.

LTBP4

This project focuses on targeting inflammation and fibrosis – two key challenges in Duchenne.

HT-100

Pre-clinical research for drug to target muscle fibrosis.

Our commitment

We are passionate about supporting the most promising research to find therapies, power clinical trials and improve care for Duchenne muscular dystrophy. We aim to focus our efforts on tackling Duchenne for all patients, regardless of their type of mutation. We have an open grant call and all applications are peer reviewed.

Our scientific advisory board comprises leading minds in the field: Professor Ronald Cohn, Dr Kevin Campbell, Professor Madeleine Durbeej-Hjalt and Dr James Dowling together with our Honorary Scientific Patron Professor Victor Dubowitz. Read more about their work here. Please contact research [at] duchenne.org.uk for more information about applications.

Our mission

We aim to stop Duchenne muscular dystrophy being a death sentence for hundreds of thousands of boys worldwide.

Our impact

We are helping turn the hope of treatments into reality. Critical treatments are in clinical trial thanks to our funds.

Your help

Your generosity has funded millions of pounds worth of ground-breaking research.
And there is still work to do.